| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
Ipsapiron reduces the behavioral effects in both normal and reserpine rats Stampede) that are induced by 8-OH-DPAT and 5-methoxydimethyltryptamine (5-HT1A receptor agonist), such as flattened body posture and forepaws[1]. Rats given ixabepilone (2.5–80 mg/kg) alone showed a small flattening of the body posture (about 1 point at the highest dose), and at doses between 2.5 and 80 mg/kg, there was also a slight abduction of the hindlimb. In rats and mice, ixabepilone given alone at low dosages (2.5–10 mg/kg ip) did not significantly change body temperature; but, at high doses (35 mg/kg ip), it reduced body temperature in both species by around 10%. 2-2.5 °C [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male albino Swiss mice (18-24 g) and male Wistar rats (160-200 g) [1].
Doses: 5 and 10 mg/kg. Route of Administration: IP 30 minutes before injection of 8-OH-DPAT and 5-MeODMT. Experimental Results: Rat behavioral responses (flattened body posture, forepaw stepping) to 8-OH-DPAT (5 mg/kg sc) were antagonized by Ipsapirone (5 and 10 mg/kg ip). |
| References |
|
| Additional Infomation |
1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one is a N-arylpiperazine.
|
| Molecular Formula |
C19H23N5O3S
|
|---|---|
| Molecular Weight |
401.48
|
| Exact Mass |
401.152
|
| Elemental Analysis |
C, 56.84; H, 5.77; N, 17.44; O, 11.95; S, 7.99
|
| CAS # |
95847-70-4
|
| Related CAS # |
92589-98-5 (HCl);95847-70-4;
|
| PubChem CID |
56971
|
| Appearance |
White to off-white solid powder
|
| Density |
1.345g/cm3
|
| Boiling Point |
629.8ºC at 760mmHg
|
| Flash Point |
334.7ºC
|
| Index of Refraction |
1.622
|
| LogP |
2.245
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(CCCCN2CCN(C3N=CC=CN=3)CC2)S(=O)(=O)C2C1=CC=CC=2
|
| InChi Key |
TZJUVVIWVWFLCD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H23N5O3S/c25-18-16-6-1-2-7-17(16)28(26,27)24(18)11-4-3-10-22-12-14-23(15-13-22)19-20-8-5-9-21-19/h1-2,5-9H,3-4,10-15H2
|
| Chemical Name |
1,1-Dioxo-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2-benzothiazol-3-one
|
| Synonyms |
IpsapironeBAY q 7821 BAY q7821BAY q-7821
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~62.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4908 mL | 12.4539 mL | 24.9078 mL | |
| 5 mM | 0.4982 mL | 2.4908 mL | 4.9816 mL | |
| 10 mM | 0.2491 mL | 1.2454 mL | 2.4908 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
